Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

30 Aug 2012

Abstract excerpt

PURPOSE: A deregulated epigenome contributes to the transformed phenotype of mantle cell lymphoma (MCL). This involves activity of the polycomb repressive complex (PRC) 2, containing three core proteins, EZH2, SUZ12, and EED, in which the SET domain of EZH2 mediates the histone methyltransferase activity. We determined the effects of 3-deazaneplanocin A (DZNep), an S-adenosylhomocysteine hydrolase inhibitor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22932665
DOI: 10.1158/1078-0432.ccr-12-0873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma CellsPMID 22932665Read ↗

Targeting of cancer stem cells by inhibitors of DNA and histone methylationSemantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated LymphomasSemantic proximity Read ↗

Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell LymphomaSemantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Semantic proximity Read ↗

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.